Lineage Cell Therapeutics (LCTX) EBIT (2010 - 2026)

Lineage Cell Therapeutics' EBIT history runs 17 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, EBIT fell 16.73% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 76.85% YoY), while the FY2025 annual figure was -$36.6 million, down 70.5% from the prior year.
• EBIT for Q1 2026 stood at -$7.6 million, down from -$6.5 million in the prior quarter.
• The five-year high for EBIT was -$3.8 million in Q3 2025, with the low at -$19.8 million in Q2 2025.
• The 5-year median for EBIT is -$6.4 million (2022), against an average of -$6.6 million.
• The sharpest annual moves came in 2022 and 2025: EBIT jumped 76.49% in 2022, then plunged 237.14% in 2025.
• Lineage Cell Therapeutics' EBIT stood at -$6.6 million in 2022, then increased by 4.17% to -$6.4 million in 2023, then climbed by 19.68% to -$5.1 million in 2024, then dropped by 28.14% to -$6.5 million in 2025, then slipped by 15.96% to -$7.6 million in 2026.
• Business Quant data shows LCTX's EBIT at -$7.6 million in Q1 2026, -$6.5 million in Q4 2025, and -$3.8 million in Q3 2025.